XBIT (XBiotech) Research & Development: $40.98 Mil (TTM As of Mar. 2026)


XBIT XBiotech Inc XBIT
32 GF Score
Price $2.34
! 2 Warning Signs
View Full Analysis

What is XBiotech Research & Development?

XBiotech XBIT +0.65% 32 Research & Development is $40.98 Mil as of Mar. 2026. GuruFocus rates XBIT with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. XBiotech's Research & Development for the three months ended in Mar. 2026 was $5.21 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $40.98 Mil.

XBiotech  (NAS:XBIT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

XBiotech Research & Development Related Terms

XBiotech Research & Development Historical Data

* Premium members only.

The historical data trend for XBiotech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XBiotech Research & Development Chart

XBiotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.27 31.54 32.85 37.76 47.39

XBiotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.62 5.34 5.08 25.36 5.21
XBIT
32GF Score
XBiotech Inc XBIT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XBiotech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $40.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $40.98 Mil mean?
XBiotech (XBIT) has a Research & Development of $40.98 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on XBiotech and its competitors.
Is XBiotech's Research & Development too high?
XBiotech's current Research & Development is $40.98 Mil. Overall, XBiotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does XBiotech's Research & Development compare to FLNA and MCRB?
XBiotech's Research & Development of $40.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on XBiotech and its competitors. XBiotech's current Research & Development is $40.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XBiotech stock overvalued right now?
XBiotech (XBIT) has a current Research & Development of $40.98 Mil. The current Research & Development is $40.98 Mil. XBiotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For XBiotech (XBIT), the current Research & Development is $40.98 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XBiotech Business Description

Other Exchanges 4XB:Germany
Address 5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
32GF Score

Get the complete analysis for XBIT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price